On March 5, 2026, a new initiative named HealthTech Bridge was announced in Fayetteville, Arkansas. This program aims to accelerate the clinical validation and market readiness of international health technology companies entering the U.S. market. A collaboration between HTA and Venture Atlas Labs, HealthTech Bridge connects these companies with leading U.S. clinical partners and provides opportunities for evidence generation and strategic market entry.
The program will soon open applications for its inaugural Rural Health Program, which targets innovations aimed at enhancing cardiometabolic health in rural communities. This initiative recognizes the unique challenges faced by these areas, including limited access to healthcare, workforce shortages, and infrastructure constraints.
Tailored Support for International Healthtech Companies
HealthTech Bridge differentiates itself from traditional accelerators by focusing specifically on the needs of international scale-ups. It offers structured clinical validation opportunities, such as pilot studies and real-world clinical evaluations, alongside comprehensive commercialization support. This includes reimbursement planning, investor readiness, and go-to-market strategies.
According to Elizabeth Jennings, Managing Partner of Venture Atlas Labs, entering the U.S. healthcare market requires a fundamental rethinking of commercialization strategies. She stated, “For international healthtech companies, entering the U.S. market isn’t just about scaling what already works. It requires rethinking commercialization from the ground up.” Jennings emphasized the complexities of the U.S. healthcare system, describing it as “opaque and often unforgiving” for models designed outside the country.
Jeff Stinson, Director of HTA, highlighted the importance of clinical evidence in healthcare innovation. “HealthTech Bridge is designed to help international founders not just understand the U.S. market, but generate the clinical proof and provider partnerships that accelerate adoption, reimbursement, and investor confidence,” he explained.
Focus on Rural Health
The first cohort of the program, the Rural Health Program, intends to bridge the gap between innovative health technologies and rural healthcare providers. This initiative will facilitate clinical evaluations and pilot implementations in these settings, helping to gather essential data that can inform product development and deployment strategies.
Participating organizations will gain early access to real-world data and feedback, which is crucial for refining their offerings and establishing future commercial relationships. By addressing the specific needs of underserved populations, the program aims to improve healthcare outcomes in rural areas.
HealthTech Bridge is designed for startups and scale-ups that have already demonstrated traction outside the United States but require assistance with navigating the clinical, regulatory, and commercial complexities of the U.S. healthcare market. The program includes a structured curriculum focused on international needs, mentorship from experienced healthcare leaders, and facilitated clinical studies with U.S. provider organizations.
With its commitment to fostering international health innovation, HealthTech Bridge represents a significant step forward for health technology companies looking to make an impact in the U.S. market. For more information about the program and application details, visit healthtechbridge.com.
HTA has a history of facilitating real-world clinical partnerships and research collaborations, with its flagship accelerator, HeartX, supporting cardiovascular-focused startups. Venture Atlas Labs assists healthcare innovators in scaling their operations in the U.S. and Europe, offering guidance on health economics, regulatory structuring, and strategic advice.
